Loading...
Assessment of plasma biomarkers is emerging as a potential noninvasive way to determine risk for dementia. To further evaluate the utility of plasma biomarkers in this setting, researchers analyzed whether plasma amyloid-β40, amyloid β42, total tau, and neurofilament light chain (NfL) levels were associated with all-cause dementia and Alzheimer disease (AD) risk in 4444 participants without dementia in the Rotterdam population-based cohort study. At baseline, the average age of participants was 72 years, 9% had mild cognitive impairment (MCI), 58% were female, and 26% were apolipoprotein ℇ4 carriers.
During a median follow-up of ≈7 years, key results were as follows:
≈12% of participants developed incident dementia, among whom 68% had AD.
In a…